tbuckley/cabot-search huggingface dataset:
Outbreak of acute gastroenteritis in an Austrian boarding school, September 2006
Authors: D Schmid, E Gschiel, M Mann, S Huhulescu, W Ruppitsch, G Bohm, J Pichler, I Lederer, G Höger, S Heuberger, F Allerberger
Journal: Eurosurveillance (2007)

An outbreak of acute gastroenteritis occurred in September 2006 in a boarding school in eastern Austria. Of 113 cases, 101 were hospitalised. In order to identify the outbreak source, a retrospective cohort study on the group at risk was performed, including 222 pupils and 30 staff members. Food exposure in the canteen of the school was identified as the most relevant common link among the cases in the case series investigation. Although the preliminary microbiological investigation made Norovirus infections possible, an in-depth descriptive epidemiological investigation later pointed to food intoxication rather than a viral infection as the cause of the outbreak. The analytical epidemiological investigation implicated boiled rice and chicken wings served in the canteen as the most likely source of the outbreak. Staphylococcus aureus was identified as the causative agent. Further molecular characterisation revealed that the predominant S. aureus type in this outbreak was a new spa type, t2046. The same spa type was isolated from stool specimens of the majority of the cases investigated, from samples of the incriminated boiled rice, and also from a swab of a palmar skin lesion of one of the healthy kitchen workers, who is therefore the most likely source of contamination. This outbreak underlines again the importance of compliance with the basic guidelines for kitchen hygiene.
Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data
Authors: Anthony Matthews, Emily Herrett, Antonio Gasparrini, Tjeerd Van Staa, Ben Goldacre, Liam Smeeth, Krishnan Bhaskaran
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To quantify how a period of intense media coverage of controversy over the risk:benefit balance of statins affected their use. <b>Design</b>&nbsp;Interrupted time series analysis of prospectively collected electronic data from primary care. <b>Setting</b>&nbsp;Clinical Practice Research Datalink (CPRD) in the United Kingdom. <b>Participants</b>&nbsp;Patients newly eligible for or currently taking statins for primary and secondary cardiovascular disease prevention in each month in January 2011-March 2015. <b>Main outcome measures</b>&nbsp;Adjusted odds ratios for starting/stopping taking statins after the media coverage (October 2013-March 2014). <b>Results</b>&nbsp;There was no evidence that the period of high media coverage was associated with changes in statin initiation among patients with a high recorded risk score for cardiovascular disease (primary prevention) or a recent cardiovascular event (secondary prevention) (odds ratio 0.99 (95% confidence interval 0.87 to 1.13; P=0.92) and 1.04 (0.92 to 1.18; P=0.54), respectively), though there was a decrease in the overall proportion of patients with a recorded risk score. Patients already taking statins were more likely to stop taking them for both primary and secondary prevention after the high media coverage period (1.11 (1.05 to 1.18; P&lt;0.001) and 1.12 (1.04 to 1.21; P=0.003), respectively). Stratified analyses showed that older patients and those with a longer continuous prescription were more likely to stop taking statins after the media coverage. In post hoc analyses, the increased rates of cessation were no longer observed after six months. <b>Conclusions</b>&nbsp;A period of intense public discussion over the risks:benefit balance of statins, covered widely in the media, was followed by a transient rise in the proportion of people who stopped taking statins. This research highlights the potential for widely covered health stories in the lay media to impact on healthcare related behaviour.
P-153 Regorafenib in the real-life clinical practice: data from the czech registry
Authors: T. Buchler, Z. Bortlicek, K. Hejduk, B. Melichar, P. Pokorna, Z. Linke, L. Petruželka, J. Finek, J. Prausova, K. Kubáčková
Journal: Annals of Oncology (2016)
Histology and Cytochemistry of Human Skin. I. Metachromasia in the Mons Pubis&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: William Montagna, Herman B. Chase, Helen P. Melaragno
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article Histology and Cytochemistry of Human Skin. I. Metachromasia in the Mons Pubis Get access William Montagna, William Montagna Arnold Biological Laboratory, Brown University, Providence, R. I. Search for other works by this author on: Oxford Academic PubMed Google Scholar Herman B. Chase, Herman B. Chase Arnold Biological Laboratory, Brown University, Providence, R. I. Search for other works by this author on: Oxford Academic PubMed Google Scholar Helen P. Melaragno Helen P. Melaragno Arnold Biological Laboratory, Brown University, Providence, R. I. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 3, December 1951, Pages 591–597, https://doi.org/10.1093/jnci/12.3.591 Published: 01 December 1951 Article history Received: 06 August 1951 Published: 01 December 1951
P1132 : Regulation of oxidative stress and lipid peroxidation in methotrexate-induced liver toxicity by pretreatment with turmeric
Authors: A. Rezaei Moghadam, A. Hamraghani, M. Khajoie Najad, M. Yazdi, J. Alizadeh, H. Marzban, M.J. Łos, S. Ghavami
Journal: Journal of Hepatology (2015)
Case 39-1984
Journal: New England Journal of Medicine (1984)

Presentation of Case A 29-year-old woman was admitted to the hospital because of myalgia and muscle weakness. She was well until three weeks earlier, when she awoke with pain in the lumbar region and abdomen that increased during the day. On the following day the pain extended into the proximal portions of the thighs. She entered another hospital, where she was treated for a urinary-tract infection with ampicillin. Shortly after admission two generalized grand mal seizures were observed. The sodium was 107 mmol per liter. An electroencephalogram was reported to be mildly abnormal, without focal or seizure activity. Phenytoin sodium . . .
Chemotherapy-Induced Nausea and Vomiting
Authors: MaryAnn B. Wilbur, Michael J. Birrer, David R. Spriggs
Journal: New England Journal of Medicine (2016)

This interactive feature offers a case vignette accompanied by essays that support either using a standard premedication regimen or adding olanzapine to prevent nausea and vomiting. Share your comments and vote at NEJM.org.
Thoracic lymph node visualization after a peritoneal leak study.
Authors: ELLEN GERETY, ALAN SIEGEL
Journal: Clinical Nuclear Medicine (2001)

From the Department of Radiology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire Received for publication February 23, 2000. Revision accepted June 16, 2000. Address reprint requests to Alan Siegel, M.D., Department of Radiology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire 03756. E-mail: [email protected]
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers
Authors: Peter C. Enzinger, Barbara Ann Burtness, Donna Niedzwiecki, Xing Ye, Kathe Douglas, David H. Ilson, Victoria Meucci Villaflor, Steven J. Cohen, Robert J. Mayer, Alan Venook, Al Bowen Benson, Richard M. Goldberg
Journal: Journal of Clinical Oncology (2016)

Purpose To determine the optimal chemotherapy backbone for testing in future US cooperative group studies for metastatic esophageal and gastroesophageal junction cancers. Cetuximab was added to each treatment arm based on promising preclinical data. Patients and Methods Patients with previously untreated metastatic esophageal or gastroesophageal junction cancer were randomly assigned at a one-to-one-to-one ratio to epirubicin, cisplatin, and continuous-infusion fluorouracil (ECF), irinotecan plus cisplatin (IC), or FOLFOX (oxaliplatin, leucovorin, and bolus and infusional fluorouracil). All treatment programs included cetuximab once per week. The primary end point was response rate. Secondary outcomes included overall survival, progression-free survival, time to treatment failure, and safety. As prespecified, primary and secondary analyses were conducted only among patients with adenocarcinoma. Results This study randomly assigned 245 patients, including 222 with adenocarcinoma. Among patients with adenocarcinoma, response rate was 60.9% (95% CI, 47.9 to 72.8) for ECF plus cetuximab, 45.0% (95% CI, 33.0 to 57.0) for IC plus cetuximab, and 54.3% (95% CI, 42.0 to 66.2) for FOLFOX plus cetuximab. Median overall survival was 11.6, 8.6, and 11.8 months; median progression-free survival was 7.1, 4.9, and 6.8 months; and median time to treatment failure was 5.6, 4.3, and 6.7 months for each of these arms, respectively. FOLFOX plus cetuximab required fewer treatment modifications compared with ECF plus cetuximab and IC plus cetuximab (P = .013), and fewer patients were removed from treatment because of an adverse event or experienced treatment-related death. Conclusion In combination with cetuximab, ECF and FOLFOX had similar efficacy, but FOLFOX was better tolerated. Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested.
Case 6-1980
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Steven E. Come, John C. Long
Journal: New England Journal of Medicine (1980)

Presentation of CaseA 24-year-old man was admitted to the hospital because of an abdominal mass.Eleven years previously he was seen at another hospital because of dyspnea. Physical examination revealed right supraclavicular lymphadenopathy and slight splenomegaly. An x-ray film of the chest showed a mediastinal mass. A biopsy of a supraclavicular lymph node disclosed Hodgkin's disease, nodularsclerosis type. A lymphangiographic study was negative. A laparotomy was not performed, and Stage 2A was assigned. Radiation treatment in a dose of 4000 rem was administered to the uppermantle area and to para-aortic lymph nodes; no chemotherapy was given.During the next . . .
Patient-Derived Xenografts (PDX) of B Cell Lymphoma in NSG Mice: A Mouse Avatar for Developing Personalized Medicine
Authors: Rachel Gerstein, Zheng Zhou, Hong Zhang, Andrew Evens, Nicole Walsh, Leonard Shultz, Rita Bortell, Michael Brehm, Jan Cerny, Giles Whalen, Jack Leonard, Bruce Woda, Dale Greiner, Alan G. Rosmarin
Journal: Blood (2015)
A Central Scar in Hepatic Focal Nodular Hyperplasia Detected on Liver SPECT Imaging
Authors: YU-ERH HUANG, PEI-WEN WANG, HSU-HUA HUANG, YU-FAN CHENG, CHIANG-HSUAN LEE
Journal: Clinical Nuclear Medicine (2001)

HUANG, YU-ERH M.D.; WANG, PEI-WEN M.D.; HUANG, HSU-HUA M.D.; CHENG, YU-FAN M.D.; LEE, CHIANG-HSUAN M.D. Author Information
Case 39-1965
Authors: Donald F. Tapley, Austin L. Vickery
Journal: New England Journal of Medicine (1965)

Presentation of CaseA sixty-nine-year-old woman was admitted to the hospital because of mental confusion.She had been well until ten years previously, when loss of scalp hair began, eventuating in complete baldness five years later. At that time she was given "liver injections" because of anemia and difficulty in walking. For several years before entry she complained of weakness and fatigue. Three years before admission hoarseness and somnolence developed. Two years later constipation occurred, and for several months before admission she was markedly anorectic. Three weeks before entry she was incontinent of feces. On the day of admission she . . .
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
Authors: Al B. Benson, Igor Kiss, John Bridgewater, Ferry A.L.M. Eskens, Carolyn Sasse, Sandra Vossen, Jihong Chen, Chip Van Sant, Howard A. Ball, Anne Keating, Andrew Krivoshik
Journal: Clinical Cancer Research (2016)

Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial of tivozanib/mFOLFOX6 versus bevacizumab/mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (mCRC) evaluated tivozanib activity versus bevacizumab.Treatment-naïve patients received mFOLFOX6 every 2 weeks of each 28-day cycle plus either tivozanib orally 1.5 mg once daily for 21 days or bevacizumab intravenously 5 mg/kg every 2 weeks. Investigator-assessed progression-free survival (PFS) was the primary endpoint; some secondary endpoints included safety, overall survival, overall response rate (ORR), duration of response, time to treatment failure, and biomarker subgroup analyses.A prespecified interim futility analysis demonstrated that the futility boundary for superiority of tivozanib/mFOLFOX6 over bevacizumab/mFOLFOX6 for PFS in the intent-to-treat population was crossed; median PFS was 9.4 versus 10.7 months [HR = 1.091; confidence interval (CI), 0.693-1.718; P = 0.706]. Tivozanib/mFOLFOX6 resulted in PFS and ORR comparable with bevacizumab/mFOLFOX6; interim analyses biomarker results revealed no significant PFS association. Post hoc final analyses demonstrated a potential difference in tivozanib-specific PFS in patients with low neuropilin-1 (NRP-1), but not in patients with high NRP-1. Tivozanib/mFOLFOX6 was tolerable and adverse events were comparable with both bevacizumab/mFOLFOX6 and previous tivozanib studies.The efficacy of tivozanib/mFOLFOX6 was comparable with but not superior to bevacizumab/mFOLFOX6 in patients with previously untreated mCRC. Since data from the prespecified interim analysis did not demonstrate superiority, this resulted in discontinuation of the study. The safety and tolerability profile of tivozanib/mFOLFOX6 was consistent with other tivozanib trials. NRP-1 is a potential predictive biomarker for tivozanib activity, but these results require further validation. Clin Cancer Res; 22(20); 5058-67. ©2016 AACR.
Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation?
Authors: A S Freedman, L M Nadler
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.10.1841 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8105033 Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? A S FreedmanxA S FreedmanSearch for articles by this author , L M NadlerxL M NadlerSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.10.1841 First Page PDF © 1993 by American Society of Clinical Oncology
Commonly used drugs and supplements can worsen heart failure, US doctors warn
Authors: Michael McCarthy
Journal: BMJ (2016)

Many commonly used drugs, over-the-counter (OTC) drugs, and complementary or alternative medicine (CAM) products can cause or worsen heart failure, the American Heart Association said in its first scientific statement on the risks such products may pose to patients with heart failure.1

The statement said that “healthcare providers should conduct comprehensive medication reconciliation at each clinical visit and with each admission. Patients should be specifically asked about drug, dose, and frequency of all their medications, including OTC drugs and CAMs.”

Patients with heart failure often have other conditions—such as …
Downregulation of mTOR and P70S6Kβ2 in Pediatric T-Cell Acute Lymphoblastic Leukemia (T-ALL) Is Correlated with a Poor Prognosis
Authors: Paola Bonaccorso, Manuela Tumino, Angela D'Ambra, Elena Mirabile, Martina Barchitta, Amelia Poli, Daria Bottino, Manuela La Rosa, Antonella Agodi, Luca Lo Nigro
Journal: Blood (2011)
Cochrane corner: interventions for the management of malignant pleural effusions
Authors: Amelia O Clive, Rahul Bhatnagar, Nancy J Preston, Nick A Maskell, Hayley E Jones
Journal: Thorax (2016)

Optimal management of symptomatic malignant pleural effusions remains an important issue as it affects a significant number of patients each year internationally. The overall survival remains poor, necessitating an evidence based treatment strategy that provides the best outcomes for individual patients. This paper summarises the results of the recently published Cochrane review on interventions in malignant pleural effusions.
A Study of Aminopeptidase Activity in the Stroma of Neoplastic Tissue, With a Comparison of Histochemical Techniques&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: G G GLENNER, M S BURSTONE, D B MEYER
Journal: JNCI Journal of the National Cancer Institute (1959)

A histochemical examination of aminopeptidase activity in over 120 benign and malignant tumors revealed intense peptidase activity in the stroma adjacent only to those tumors showing invasive characteristics. The method also demonstrated that certain human tumors, such as carcinoma of the stomach, colon, and breast, and a meningioma had aminopeptidase activity within the tumor cells proper. Aminopeptidase activity in the stroma adjacent to invasive tumor is evidence of proteolysis and suggests that a prominent mechanism of tumor invasion is by the proteolytic destruction of the stromal compartment. However, this does not imply that all invasive tumors show increased stromal aminopeptidase activity, for other enzyme mechanisms not demonstrable by the present technique may be responsible for stromal dissolution in certain tumor types. It is possible that stromal proteolysis may be elicited by a factor elaborated by tumor cells which activates the peptidase, or may represent activation as the result of an immune response. Histochemically demonstrable stromal proteolytic activity may be correlated with the invasive capacity of the tumor, but is not related to its grade of anaplasia or the extent of adjacent fibroplasia. The aminopeptidase activity demonstrated histochemically by using l-leucyl-β-naphthylamide has not been identified as “leucine” aminopeptidase since neither metal-ion dependence nor relative amino acid substrate specificity correlates with that defined by Smith et al. The new modification for the histochemical demonstration of aminopeptidase activity on fresh frozen and frozen-dried tissue sections is compared with a method utilizing an inhibitory, slow-coupling diazonium salt, and the inherent errors in interpretation when using the latter method are described.
Rituximab-induced hepatitis C virus reactivation in HCV-positive patients with diffuse large B-cell lymphoma.
Authors: Rasha Mohamed Haggag, Fouad Abu-Taleb, Hussein Mustafa Khaled
Journal: Journal of Clinical Oncology (2016)

e19039 Background: The clinical outcome and hepatic toxicity occurrence of diffuse large B-cell lymphoma (DLBCL) patients with hepatitis C virus (HCV) infection in the rituximab era remains controversial. Methods: To elucidate the characteristics of DLBCL patients in relation to HCV infection status, we retrospectively analyzed DLBCL patients diagnosed and treated with chemo- or immunochemotherapy at our institutes and at a private hospital during the last decade. Of the 132 patients, 64(48.5%) and 68 (51.5%) patients received RCHOP and CHOP, respectively. Results::In all, HCV infection was identified in 35(26.5%) of 132 DLBCL patients. Except for being more likely to present with B symptoms and splenic involvement, patients with HCV infection were demographically indistinguishable from HCV-negative patients. Multivariate analysis of the whole group showed 3 factors found to independently predict an inferior OS including extra-nodal involvement ( ≤ 1 vs. > 1; HR = 4.5, 95% CI = 1.6-12.6, p = 0.012 ) , splenic involvement( presence vs. absence; HR = 0.5, 95% CI = 0.33-0.82 , p = 0.0008) , and performance status (0-1 vs. > 1; HR = 2.9, 95% CI = 1.6-12.6 ,p = 0.04). Adverse effects on DFS was significant only with splenic involvement (presence vs. absence; HR = 0.6, 95% CI = 0.45-0.9, p = 0.04). Among the HCV-infected patients, the incidence of hepatitis flares was 40%; (14/35)patients vs. 9.3% (9/97) patientsamong the HCV-uninfected individuals (P = < 0.001). Of the 35 HCV-positive patients,14 (40%) received R-CHOPand 21 (60%) received CHOP.HCV reactivation occurred in 34.2% (11/35 patients) without any relation to treatment regimen (7 (11%) for RCHOP and 5(7.3%) for CHOP;p = 0.3). No hepatic toxicity related deathshad been reported. Conclusions: our study results demonstrated that HCV infection did not influence the clinical outcome of DLBCL patients, and its reactivation has no relation to the type of treatment.
Malignant Lymphoma
Authors: Alan C. Aisenberg
Journal: New England Journal of Medicine (1973)

LymphangiographyDespite its several shortcomings, lymphangiography has come into general use over the past 10 years and has markedly altered our understanding of lymphomas. Approximately one patient with Hodgkin's disease in three is advanced from Stage I or II into Stage III because of an abnormal lymphangiogram.61,67 It is unfortunate that most of the published information on lymphangiography predates laparotomy, since, without biopsy verification, interpretation of these complex radiographic patterns is subjective. However, at present a number of points appear established (in Hodgkin's disease) from correlations made with laparotomy and subsequent clinical course. First of all, if positive interpretations are . . .
Arabinosyl cytosine: a 20-year update.
Authors: E J Freireich
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.4.523 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3470440 Arabinosyl cytosine: a 20-year update. E J FreireichxE J FreireichSearch for articles by this author https://doi.org/10.1200/JCO.1987.5.4.523 PDF "Arabinosyl cytosine: a 20-year update.." Journal of Clinical Oncology, 5(4), pp. 523–524© 1987 by American Society of Clinical Oncology
High IGSF4 expression In Pediatric Acute Monoblastic Leukemia with t(9;11)
Authors: Eva A Coenen, Jenny Kuipers, Brian V Balgobind, Jan Stary, Andre Baruchel, Valerie de Haas, Evelina S. De Bont, Dirk Reinhardt, Gertjan J. Kaspers, Jacqueline Cloos, Astrid Danen-van Oorschot, Monique L. Den Boer, Rolf Marschalek, Claus Meyer, Rob Pieters, Christian M. Zwaan, Marry van den Heuvel-Eibrink
Journal: Blood (2010)